Cytosorbents Crp

CTSO

CytoSorbents Corporation is a publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011) -- a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful substances from the blood.The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as dialysis or ECMO. A few similar products exist, including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis.CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.

Cytosorbents Crp has been a target of short sellers for a while. The current short interest of 73.19% is slightly above the average of the last 12 months (62.64%).